Q-omics provides the consensus-scored ZNF350-AS1 profile across patient tissues and cancer cell-line models. ZNF350-AS1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZNF350-AS1 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, ZNF350-AS1 RNA expression shows 16,453 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRP, and THYM as cancer lineages where ZNF350-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF350-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF350-AS1 survival associations across molecular data types. ZNF350-AS1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF350-AS1 RNA expression–survival associations across cancer types. High ZNF350-AS1 expression shows unfavorable associations in ACC, but favorable associations in UVM, HNSC, READ, THYM and BLCA. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZNF350-AS1 RNA expression.
This table summarizes ZNF350-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF350-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF350-AS1 shows lower tumor expression in KIRP, KICH, KIRC and THCA and higher tumor expression in LIHC and BRCA. The KIRP box plot shows higher ZNF350-AS1 RNA expression in normal versus tumor tissue (log2 FC = −1.980, t-test p < 0.001).
This table shows molecular features associated with ZNF350-AS1 in patient tissues and cancer cell lines. In patient samples, ZNF350-AS1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
